EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study

Konstantin Agelopoulos, Leigh Nattkemper, Felix Witte, Claudia Zeidler, Jerry Bagel, Amy H Praestgaard, Gabriel Bologna, Madison Mack, Joseph Zahn, Annie Zhang, Gil Yosipovitch, Sonja Ständer

British Journal of Dermatology · 18.08.2026 · 195 (3) · 537-539

DOI: 10.1093/bjd/ljag256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 23.06.2026. Verfasst von Konstantin Agelopoulos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Better understanding of the dysregulation of neuroimmune mechanistic pathways in patients with atopic dermatitis (AD) and chronic itch is needed. The aim of this study is to assess the changes in neuronal architecture after dupilumab treatment in patients with AD and chronic itch: the primary endpoint was change from baseline in intraepidermal nerve fibre density (IENFD). We observed that dupilumab treatment significantly increased IENFD in the lesional skin of patients with AD, with IENFD at end of treatment being comparable with healthy controls, and improved clinical signs and itch.

Autor:innen und Institutionen

  • Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.
  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami, Miami, FL, USA.
  • Eczema Treatment Center of New Jersey, East Windsor, NJ, USA.
  • Sanofi, Cambridge, MA, USA.
  • Ividata Life Science (contracted for Sanofi), Levallois-Perret, France.
  • Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.

Förderung

  • Deutsche Forschungsgemeinschaft
  • German Research Foundation

Zitieren

APA

Agelopoulos, K., Nattkemper, L., Witte, F., Zeidler, C., Bagel, J., Praestgaard, A. H., Bologna, G., Mack, M., Zahn, J., Zhang, A., Yosipovitch, G., & Ständer, S. (2026). Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study. British Journal of Dermatology, 195(3), 537-539. https://doi.org/10.1093/bjd/ljag256

Vancouver

Agelopoulos K, Nattkemper L, Witte F, Zeidler C, Bagel J, Praestgaard AH, et al. Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study. British Journal of Dermatology. 2026;195(3):537-539. doi:10.1093/bjd/ljag256

BibTeX
@article{Agelopoulos2026,
  author = {Agelopoulos, Konstantin and Nattkemper, Leigh and Witte, Felix and Zeidler, Claudia and Bagel, Jerry and Praestgaard, Amy H and Bologna, Gabriel and Mack, Madison and Zahn, Joseph and Zhang, Annie and Yosipovitch, Gil and Ständer, Sonja},
  title = {Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory study},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {3},
  pages = {537--539},
  doi = {10.1093/bjd/ljag256}
}
Kostenlos starten →